Home » K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

June 16, 2006

Analysts at Deutsche Bank Securities maintain their "hold" rating on K-V Pharmaceutical. The target price has been reduced from $26 to $20.
Newratings

KEYWORDS Daily International Pharma Alert

26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

K-V PHARMACEUTICAL 'HOLD,' TARGET PRICE REDUCED

Upcoming Events

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

FDA Clears SCC’s Transfusion-Management Software

MiRXES Earns CE Mark for COVID-19/Flu Test

Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

The Revised ICH E8: A Guide to New Clinical Trial Requirements